← Leaderboards
Harrison W Farber
Boston University Medical Campus
$4,369,797
Attributed
$4,488,217
Total exposure
5
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $556.7K · FY2005–17$1M$750K$500K$250K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
Funding mix
By agency
NIH$4,488,217 · 5
By mechanism
R01$1,954,974 · 2
P50$1,515,339 · 1
U54$781,064 · 1
R21$236,840 · 1
Top collaborators
- Robert A Lafyatis1 shared
Most similar at Boston University Medical Campus
Same institution · by research overlap
- Jag Bhawan$906,097
- Joseph A. Vita$19,118,512
- Susan P Perrine$12,101,972
- Robert A Lafyatis$10,905,922
- Raphael A Zoeller$1,510,292
Others in their field
Top investigators on “Proteins”
- David Heimbrook · Leidos Biomedical Research, Inc.$354,061,551
- Randall J Bateman · Washington University$187,292,085
- Paul S. Aisen · Cognition Therapeutics, Inc.$175,382,342
- Reisa A. Sperling · Banner Health$145,046,481
- Barton F Haynes · Duke University$136,029,850
- Joseph L Goldstein · University Of Texas Sw Med Ctr/Dallas$102,433,280
Research focus
ProteinsLungBlood VesselsResponseEndothelial CellsSystemic SclerodermaPulmonary Arterial HypertensionFibrosisFunctional DisorderLongevityMolecularAntioxidantsInjuryVascular DiseasesHypoxiaInterstitial Lung DiseasesInflammationInflammatoryComplicationInvestigationPathway InteractionsApoptosisDiffuse SclerodermaDisease Phenotype
Grant awards (15)
Dimethyl Fumarate In Systemic Sclerosis-Associated Pulmonary Arterial Hypertension$236,840
R21 · FY2017 · AR
Biomarkers of Pulmonary Complications of Scleroderma: The SSc-PAH and$279,961
P50 · FY2015 · AR · contact PI
Biomarkers of Pulmonary Complications of Scleroderma: The SSc-PAH and$289,730
P50 · FY2014 · AR · contact PI
Biomarkers of Pulmonary Complications of Scleroderma: The SSc-PAH and$299,406
P50 · FY2013 · AR · contact PI
Biomarkers of Pulmonary Complications of Scleroderma: The SSc-PAH and$320,154
P50 · FY2012 · AR · contact PI
Biomarkers of Pulmonary Complications of Scleroderma: The SSc-PAH and$326,088
P50 · FY2011 · AR · contact PI
Oxidant State and Nitric Oxide Metabolism in the Acute Chest Syndrome$322,073
U54 · FY2007 · HL · contact PI
Endothelial Cell Hypoxia Tolerance: Role of Plasmalogens$394,262
R01 · FY2006 · HL · contact PI
Oxidant State and Nitric Oxide Metabolism in the Acute Chest Syndrome$157,541
U54 · FY2006 · HL · contact PI
Endothelial Cell Hypoxia Tolerance: Role of Plasmalogens$403,750
R01 · FY2005 · HL
Oxidant State and Nitric Oxide Metabolism in the Acute Chest Syndrome$152,952
U54 · FY2005 · HL
Endothelial Cell Hypoxia Tolerance: Role of Plasmalogens$403,750
R01 · FY2004 · HL
Oxidant State and Nitric Oxide Metabolism in the Acute Chest Syndrome$148,498
U54 · FY2004 · HL
Endothelial Cell Hypoxia Tolerance: Role of Plasmalogens$403,750
R01 · FY2003 · HL
ENDOTHELIAL CELL HYPOXIA ASSOCIATED PROTEINS$349,462
R01 · FY2000 · HL